PMEF
PRME icon

Point72 Middle East FZE’s Prime Medicine PRME Stock Holding History

Point72 Middle East FZE’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-37,609
Closed -$699K – 2084
2022
Q4 		$699K Buy
+37,609
New +$679K 0.03% 600

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Middle East FZE's PRME Position: Q1 2023 in Review

Point72 Middle East FZE sold out of Prime Medicine (PRME) in Q1 2023, closing a stake of 37,609 shares — an estimated $699K sold.

Point72 Middle East FZE first reported a position in PRME in Q4 2022 and held it in 1 quarter. The position peaked at $699K in Q4 2022. 76 funds tracked by Wall St. Rank hold PRME as of Q1 2023.

  • Point72 Middle East FZE reported no remaining Prime Medicine position as of Q1 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 37,609 Prime Medicine shares in Q1 2023, an estimated $699K.
  • Point72 Middle East FZE first reported a position in Prime Medicine in Q4 2022 and held it in 1 quarter.
  • Point72 Middle East FZE's Prime Medicine position peaked at $699K in Q4 2022.
  • 76 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2023.

Based on Point72 Middle East FZE's 13F filing for Q1 2023, filed 15 May 2023.